country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P99756

Copy Link Print Information

Biologically Validated

Nirsevimab

Name: Nirsevimab
Brand: MedChemExpress
SKU: HY-P99756
Price: 615.00 USD
Availability: InStock
Rating: 5 (2 reviews)

(Synonyms: MEDI8897)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC₅₀ values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.63%
CAS. Nr.: 1989556-22-0
Molecular Weight:146.31 kDa

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Nirsevimab Chemical Structure

CAS. Nr.: 1989556-22-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Accession
- Conjugated
- Reconsititution
- Format
- Anwendung
- Verified Bioactivity
Chemical Information
Publications (2)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

RSV-F

In Vitro

Nirsevimab can directly neutralize RSV virus and has fragment crystallizable (Fc) - mediated effector function, thereby preventing respiratory infections^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Nirsevimab (10-10000 μg/kg; i.m.) inhibits the antibody response in the respiratory mucosa of mice when pre-administered prior to RSV virus infection^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

3-week-old female BALB/c mice^[2].
Dosage:

10 μg/kg, 100 μg/kg, 1 mg/kg, 10 mg/kg
Administration:

Intramuscular injection (i.m.); administer medication 24 hours prior to RSV virus exposure
Result:

Inhibited the secretion of sIgA, mucosal IgA, and mucosal IgG in the offspring subsequent to the initial RSV infection.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Accession

A0A0X8XRK2

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG1 kappa

Anwendung

ELISA, FACS, Functional assay

Verified Bioactivity

Immobilized Fusion glycoprotein F0/F Protein, HRSV (sf9, His, HY-P75182) can bind Nirsevimab. The EC₅₀ for this effect is 44 ng/mL.

Chemical Information

CAS. Nr. 1989556-22-0
Appearance Liquid
Molecular Weight 146.31 kDa
Color Colorless to light yellow
SMILES

[Nirsevimab]
Synonyms

MEDI8897
Versand

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (2)

All Bio/Physico-chemical Assay

Sort by:

Journal Impact Factor

J Med Virol

Development of a HEp2-CDX Mouse Model With Sustained High RSV Viral Loads for Robust Antiviral Therapeutic Evaluation. [Abstract]

2025 Sep;97(9):e70601. PMID: 40947663
bioRxiv

2026 Feb 4.

Nirsevimab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2026 Feb 4.

All MARMs could be rescued by at least one other mAb. Three RSM01 MARMs (RSM-1 to RSM-3) could still be neutralised by nirsevimab and clesrovimab.

Nirsevimab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2026 Feb 4.

RSV-B isolates displayed 17 highly variable positions, two of which are located in overlapping RSM01/nirsevimab binding sites.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (260 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Verweise

[1]. Brady T, et al. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. Front Immunol. 2023 Oct 11;14:1283120. [Content Brief]

[2]. Ma J, et. Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure. Front Immunol. 2024 Apr 30;15:1377374. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

Nirsevimab

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Accession
- Conjugated
- Reconsititution
- Format
- Anwendung
- Biological Activity
Chemical Information
Publications (2)
Reinheit & Dokumentation
Verweise

1/16

Human IgG1 kappa
1/16

Immobilized Fusion glycoprotein F0/F Protein, HRSV (sf9, His, HY-P75182) can bind Nirsevimab. The EC₅₀ for this effect is 44 ng/mL.
1/16

Nirsevimab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2026 Feb 4.

Customer Validation
All MARMs could be rescued by at least one other mAb. Three RSM01 MARMs (RSM-1 to RSM-3) could still be neutralised by nirsevimab and clesrovimab.
1/16

Nirsevimab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2026 Feb 4.

Customer Validation
RSV-B isolates displayed 17 highly variable positions, two of which are located in overlapping RSM01/nirsevimab binding sites.
1/16

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Nirsevimab

Publications Citing Use of MedChemExpress (MCE) Nirsevimab